These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 1533532

  • 1. Early and late proarrhythmia from antiarrhythmic drug therapy.
    Morganroth J.
    Cardiovasc Drugs Ther; 1992 Feb; 6(1):11-4. PubMed ID: 1533532
    [Abstract] [Full Text] [Related]

  • 2. Proarrhythmic effects of antiarrhythmic drugs: evolving concepts.
    Morganroth J.
    Am Heart J; 1992 Apr; 123(4 Pt 2):1137-9. PubMed ID: 1553883
    [Abstract] [Full Text] [Related]

  • 3. Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis.
    Pratt CM.
    Am J Cardiol; 1990 Feb 20; 65(8):51D-55D; discussion 68D-71D. PubMed ID: 1689536
    [Abstract] [Full Text] [Related]

  • 4. What have clinical trials taught us about proarrhythmia?
    Skanes AC, Green MS.
    Can J Cardiol; 1996 Apr 20; 12 Suppl B():20B-26B. PubMed ID: 8616725
    [Abstract] [Full Text] [Related]

  • 5. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
    Peters RW, Mitchell LB, Brooks MM, Echt DS, Barker AH, Capone R, Liebson PR, Greene HL.
    J Am Coll Cardiol; 1994 Feb 20; 23(2):283-9. PubMed ID: 8294678
    [Abstract] [Full Text] [Related]

  • 6. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS, Zehender M.
    Ther Umsch; 2000 May 20; 57(5):324-32. PubMed ID: 10859993
    [Abstract] [Full Text] [Related]

  • 7. Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death.
    Prystowsky EN.
    Am J Cardiol; 1996 Oct 17; 78(8A):35-41. PubMed ID: 8903274
    [Abstract] [Full Text] [Related]

  • 8. Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias.
    Anderson JL.
    Am J Cardiol; 1990 Feb 20; 65(8):32D-40D. PubMed ID: 2106254
    [Abstract] [Full Text] [Related]

  • 9. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis.
    Morganroth J, Goin JE.
    Circulation; 1991 Nov 20; 84(5):1977-83. PubMed ID: 1834365
    [Abstract] [Full Text] [Related]

  • 10. Can antiarrhythmic drugs survive survival trials?
    Pratt CM, Waldo AL, Camm AJ.
    Am J Cardiol; 1998 Mar 19; 81(6A):24D-34D. PubMed ID: 9537220
    [Abstract] [Full Text] [Related]

  • 11. Placement of moricizine in the selection of antiarrhythmic drug therapy.
    Morganroth J.
    Am J Cardiol; 1990 Feb 20; 65(8):65D-67D; discussion 68D-71D. PubMed ID: 2407093
    [Abstract] [Full Text] [Related]

  • 12. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W, Wichter T, Chen X, Hördt M, Willems S, Rotman B, Hindricks G, Kottkamp H, Borggrefe M, Breithardt G.
    Z Kardiol; 1994 Feb 20; 83 Suppl 5():75-85. PubMed ID: 7846949
    [Abstract] [Full Text] [Related]

  • 13. Drug-induced early and late proarrhythmia.
    Morganroth J.
    Cardiol Clin; 1992 Aug 20; 10(3):397-401. PubMed ID: 1504971
    [Abstract] [Full Text] [Related]

  • 14. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA, Gillette PC, Benson DW.
    J Am Coll Cardiol; 1991 Aug 20; 18(2):356-65. PubMed ID: 1906902
    [Abstract] [Full Text] [Related]

  • 15. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia.
    Prystowsky EN.
    Clin Cardiol; 1994 Sep 20; 17(9 Suppl 2):II7-10. PubMed ID: 7882612
    [Abstract] [Full Text] [Related]

  • 16. Proarrhythmic response to antiarrhythmic drug as a risk factor for sudden cardiac death in patients with ischemic heart disease.
    Trusz-Gluza M, Giec L, Dabrowski A, Kuch J, Pasyk S, Piwowarska W, Pracka H, Sadowski Z, Wodniecki J.
    Pacing Clin Electrophysiol; 1991 Nov 20; 14(11 Pt 2):1947-50. PubMed ID: 1721204
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine).
    Morganroth J, Pratt CM.
    Am J Cardiol; 1989 Jan 15; 63(3):172-6. PubMed ID: 2642632
    [Abstract] [Full Text] [Related]

  • 18. Indications for antiarrhythmic suppression of ventricular arrhythmias: a definition of life-threatening ventricular arrhythmias.
    Morganroth J.
    Am J Cardiol; 1993 Aug 12; 72(4):3A-7A. PubMed ID: 8346724
    [Abstract] [Full Text] [Related]

  • 19. The new antiarrhythmic drugs. How to put them to the best use.
    Anderson JL.
    Postgrad Med; 1988 Mar 12; 83(4):181-93. PubMed ID: 3353335
    [Abstract] [Full Text] [Related]

  • 20. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.
    Das MK, Zipes DP.
    J Cardiovasc Pharmacol; 2010 May 12; 55(5):438-49. PubMed ID: 20509177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.